Brainstorm Cell Therapeutics Inc
Change company Symbol lookup
Select an option...
BCLI Brainstorm Cell Therapeutics Inc
EEX Emerald Holding Inc
JPM-L JPMorgan Chase & Co
SBFM Sunshine Biopharma Inc
SEKEY Seiko Epson Corp
PXMD PaxMedica Inc
CDT Conduit Pharmaceuticals Inc
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc
ALEC Alector Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimers disease (AD) and other neurodegenerative diseases. NurOwn, the Company’s cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its Phase III ALS and Phase II PMS clinical trials. Its wholly owned Israeli subsidiary, BrainStorm Cell Therapeutics Ltd., holds rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd. and two others.


Last Trade
0.0322 (7.53%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.388 (-47.57%)
Bid close
Ask close
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Chesapeake Energy stock rises, after Fitch's credit upgrade and positive outlook suggests an investment-grade rating could be on the horizon

11:14 am ET April 13, 2023 (MarketWatch)

Shares of Chesapeake Energy Corp. (CHK) rallied 1.6% toward a six-week high in morning trading Thursday, after Fitch Ratings raised the natural gas and oil company's credit rating to the highest "junk" rating, and indicated the next rating move will make it investment grade. Fitch upgraded the longer-term issuer default rating (IDR) to BB+ from BB, and said the rating outlook is positive, which implies the next move could be an upgrade. Another upgrade would take the rating to BBB-, which is the lowest investment-grade rating. "The Positive Outlook could be resolved in up to 24 months as Chesapeake continues to develop a track record in line with its post-bankruptcy emergence conservative financial policy," Fitch said. In comparison, S&P Global Ratings rates Chesapeake's credit at BB, two notches below investment grade, with a "stable" outlook, while Moody's rates the credit at Ba2, also two notches below investment grade, but with a positive outlook. Chesapeake's stock has shed 14.9% year to date, while the Energy Select Sector SPDR exchange-traded fund (XLE) has eased 0.6% and the S&P 500 has gained 7.3%.

-Tomi Kilgore

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

April 13, 2023 11:14 ET (15:14 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.